Woodline Partners’s Viridian Therapeutics VRDN Stock Holding History

Woodline Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9M	Hold	700,929	–	–	0.04%	476
2026 Q1	$13.7M	Sell	700,929 -415,000	-37%	-$12.3M	0.05%	437
2025 Q4	$34.7M	Buy	1,115,929 +300,444	+37%	+$8.24M	0.13%	196
2025 Q3	$17.6M	Hold	815,485	–	–	0.08%	310
2025 Q2	$11.4M	Buy	815,485 +1,838	+0.2%	+$24.9K	0.06%	399
2025 Q1	$11M	Hold	813,647	–	–	0.07%	345
2024 Q4	$15.6M	Sell	813,647 -5,348	-0.7%	-$116K	0.11%	256
2024 Q3	$18.6M	Buy	818,995 +418,080	+104%	+$6.84M	0.16%	203
2024 Q2	$5.22M	Sell	400,915 -38,007	-9%	-$526K	0.05%	333
2024 Q1	$7.69M	Buy	+438,922	New	+$8.51M	0.07%	307
2023 Q3	–	Sell	-168,060	Closed	-$4M	–	753
2023 Q2	$4M	Buy	168,060 +48,611	+41%	+$1.25M	0.05%	329
2023 Q1	$3.04M	Sell	119,449 -204,690	-63%	-$6.56M	0.04%	369
2022 Q4	$9.47M	Buy	324,139 +28,265	+10%	+$651K	0.13%	221
2022 Q3	$6.07M	Sell	295,874 -256,497	-46%	-$4.61M	0.08%	265
2022 Q2	$6.39M	Buy	552,371 +331,114	+150%	+$4.45M	0.1%	225
2022 Q1	$4.09M	Sell	221,257 -36,413	-14%	-$700K	0.07%	263
2021 Q4	$5.09M	Buy	+257,670	New	+$4.8M	0.07%	278

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Woodline Partners's VRDN Position: Q2 2026 in Review

Woodline Partners held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 700,929 shares worth $12.9M. The position accounts for 0.04% of the portfolio, ranked #476.

Woodline Partners first reported a position in VRDN in Q4 2021 and has held it in 17 quarters since. The position peaked at $34.7M in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Woodline Partners held 700,929 shares of Viridian Therapeutics worth $12.9M as of Q2 2026.
Woodline Partners left its Viridian Therapeutics share count unchanged in Q2 2026.
Viridian Therapeutics made up 0.04% of Woodline Partners's portfolio in Q2 2026, its #476 holding.
Woodline Partners first reported a position in Viridian Therapeutics in Q4 2021 and has held it in 17 quarters since.
Woodline Partners's Viridian Therapeutics position peaked at $34.7M in Q4 2025.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.